Navigation Links
Orchid Cellmark Reports Third Quarter 2008 Financial Results
Date:11/18/2008

PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today reported its financial results for the third quarter of 2008.

Total revenues were $14.9 million for the third quarter of 2008 compared to $15.6 million for the third quarter of 2007. The decrease in total revenues for the third quarter of 2008 compared to a year ago was largely due to lower revenues in the U.K.

Total U.S.-based revenues rose by 4% over the comparable quarter in 2007, principally due to increases in the U.S. paternity testing business. This was partially offset by lower revenues from forensic casework business as well as a decline in the company's business that generates DNA profiles for the federal CODIS (Combined DNA Index System) and state DNA databases. The decrease in U.K.-based revenues in the quarter compared to a year ago was due to lower volumes of animal DNA testing for scrapie susceptibility and slightly reduced forensics revenues due to adverse exchange rates.

Excluding cost of service revenue, operating expenses for the quarter declined to $5.8 million compared to $6.0 million for the third quarter of 2007 as a result of reduced general and administrative expenses.

Operating loss for the third quarter of 2008 was $1.4 million compared to a $466 thousand loss for the third quarter of 2007. The operating loss increase was principally due to decreases in gross margins in both the U.S. and the U.K. Gross margin for the U.S. business decreased for the third quarter of 2008 compared to the third quarter of 2007 largely as a result of a decline in the average selling prices in the CODIS and forensic casework businesses. Gross margin for the U.K. business in the quarter was adversely impacted by lower margin fore
'/>"/>

SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Saving the wild orchids of Borneo
2. Orchid Cellmark to Present at the 2008 Bank of America Health Care Conference
3. First orchid fossil puts showy blooms at some 80 million years old
4. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
5. Synaptics Reports Record Results for First Quarter of Fiscal 2009
6. GEN reports on novel tools for deciphering biological networks
7. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
8. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
9. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
10. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
11. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... to their offering. One major trend ... biometric systems. Multimodal biometric systems utilize more than one ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... from amniotic fluid were used to restore gut structure and ... in the journal Gut . The findings pave the ... serious damage from inflammation in the intestines of babies. ... investigated a new way to treat necrotizing enterocolitis (NEC), where ...
... sounds from whales and other marine mammals, using a variety ... how these animals use sound to interact with each other ... report using this technology to record spawning cod in the ... for several decades, but few studies have observed their use ...
... Catching rides on cargo ships and fishing boats, many invasive ... of our native marine life. , In a study published ... and his team examine what factors allow some invasive species ... WHY SHOULD WE CARE? Once ...
Cached Biology News:Amniotic fluid stem cells repair gut damage 2Acoustic monitoring of Atlantic cod reveals clues to spawning behavior 2Acoustic monitoring of Atlantic cod reveals clues to spawning behavior 3Invasive species: Understanding the threat before it's too late 2
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Research Campus as its newest tenant partner. The NC Research Campus ... Nine universities and colleges (including Duke University, UNC, and NC State)will have ... The Campus promises to be a world class center for industry and ... ...
... TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today announced ... a Phase I multiple dose clinical trial of NGX426, ... The trial is,designed to evaluate the safety, tolerability and ... days. NGX426 has been,safely administered to more than 150 ...
... Lawrence A. Rheins Joins Histogen Aesthetics as President , ... ... a regenerative medicine company developing solutions based on the products of ... a venture developing products for the growing medical aesthetic industries based ...
Cached Biology Technology:Food and Beverage Giant Joins Kannapolis Research Center 2Food and Beverage Giant Joins Kannapolis Research Center 3Food and Beverage Giant Joins Kannapolis Research Center 4TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 2Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 3Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 4
... is used in conjuction with Annexin V-FITC ... earlier stages of apoptosis (Annexin V positive, ... later stages of apoptosis or already dead ... detected in the orange range of the ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... CrysScreen is a software package ... user interface for custom buffer creation, ... management in crystallization trials. The software ... steps in automated protein crystallography: ...
... direct antibiotic-based selection system for recombinant identification. ... eliminating the need for costly color screening. ... to 100% accuracy in recombinant selection. pLivSelect ... colony picking. This cloning kit can be ...
Biology Products: